Value-based care results in a lot of added administrative tasks for physicians — so much so that one health system leader believes value-based care will never reach true scale unless providers figure out how to ease that burden. The adoption of new technology, coupled with workflow training from fellow physicians, can help address this issue, population health experts say.
Syntax Health's new two-sided software-as-a-service solution allows payers and providers (as well as actuaries, network managers and analysts) to collaborate in creating a value-based contract.
In today’s healthcare landscape, your choice of medical billing partner directly impacts your bottom line. What are the best medical billing outsourcing companies, and which one is right for you?
By leveraging its large membership, Medicare could by embracing value-based contracting significantly influence the pharmaceutical market, pitting competing drugs against each other, or encouraging pharmaceutical makers to figure out ways to deliver drugs more cheaply.
Cell and gene therapies are offering patients potentially curative treatments for a growing scope of diseases. Insurance companies are trying to figure out how to pay for them. Industry consultants speaking at the HLTH conference offered some strategies they see payers taking to these new therapies.
Lyfegen, a startup that provides software for value-based drug contracting, recently raised $8 million in an oversubscribed Series A financing round. With the new funds, the company — which is based in Switzerland and New York — plans to expand its presence in the U.S., where drug costs are the highest in the world.
The funding round was led by American Family Ventures and brings the company’s total funds to $20 million. With the money, TCARE will grow its team and work to expand its offerings for its existing clients.
Neurologists and health care practitioners must evolve with the world. Telemedicine carts assist in this evolution by serving as an intermediary between patients and doctors.
Value-based contracts covering the reimbursement of drugs and medical devices are slowly gaining acceptance. A panel at the MedCity News INVEST conference discussed the challenges and opportunities for these contracts, which aim to improve patient outcomes and control the cost of care.
The contracts are complicated and full of risks for drug companies. But there's also a risk to steering clear of the arrangements -- reduced or restricted access to a company's medication.
CEO Tim Peck confirmed the news to CNBC, saying the company ran out of the cash it needed to continue to scale the business and was laying off roughly 100 employees.